DOI: https://doi.org/10.22141/2224-1485.6.62.2018.153931

New possibilities in the treatment of pulmonary arterial and chronic thromboembolic pulmonary hypertension in Ukraine

G.D. Radchenko

Abstract


The aim of this paper is the review of literature data about effectiveness and safety of bosentan in the treatment of pulmonary hypertension. In addition, it considers some aspects of diagnosis, classification and pathogenesis of pulmonary hypertension. It is concluded that bosentan is effective both as monotherapy and in combination therapy of patients with pulmonary arterial hypertension. In patients with chronic thromboembolic pulmonary hypertension, it is possible to use bosentan, but positive changes are less significant than in patients with pulmonary arterial hypertension. Data about possible adverse effects of bosentan and ways to avoid them are considered.

Keywords


pulmonary hypertension; specific therapy; endothelin receptor blockers; bosentan

References


Galiè N., Humbert M., Vachiery J. et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT) // European Heart Journal. — 2015. — 37. — Р. 67-119. https://doi.org/10.1093/eurheartj/ehv317

Giaid A., Yanagisawa M., Langleben D. et al. Expression of Endothelin-1 in the lungs of patients with pulmonary hypertension // N. Engl. J. Med. — 1993. — 328. — Р. 1732-9.

Humbert M., Morrell N.W., Archer S.L. et al. Cellular and molecular pathobiology of pulmonary arterial hypertension // J. Am. Coll. Cardiol. — 2004. — 43. — Р. 13-24.

Galie N., Grigioni F., Bacchi-Rggianin K. et al. Relation of endothelin-1 to survival in patients with primary pulmonary hypertension // Eur. J. Clin. Invest. — 1996. — 26. — Р. 273.

Clozel M., Gray G.A., Breu V. et al. The endothelin ETB receptor mediates both vasodilation and vasoconstriction in vivo // Biochem. Biophys. Res. Commun. — 1992. — 186. — Р. 867-73.

Neylon C.B., Avdonin P.V., Dilley R.J. et al. Different electrical responses to vasoactive agonists in morphologically distinct smooth musclecell types // Circ. Res. — 1994. — 75. — Р. 733-41.

Levin E.R. Endothelins // N. Engl. J. Med. — 1995. — 333. — Р. 356-63.

Benigni A., Ramuzzi G. Endothelin antagonists // Lancet. — 1999. — 353. — Р. 133-8.

Filep J.G., Fournier A., Foldes-Filep E. Acute pro-inflammatory actions of endothelin-1 in the guinea pig lung: Involvement of ETA and ETB receptors // Br. J. Pharmacol. — 1995. — 115. — Р. 227-36.

Katwa L.C., Guarda E., Weber K.T. Endothelin receptors in cultured adult rat cardiac fibroblasts // Cardiovasc. Res. — 1993. — 27. — Р. 2125-9.

US Bosentan label" (PDF). FDA. October 2016. Retrieved 6 August 2017. For label updates see FDA index page for NDA 021290 "Tracleer (bosentan) 62.5 mg and 125 mg film-coated tablets". UK Electronic Medicines Compendium. May 2017. Retrieved: 6 August 2017.

Tracleer (bosentan) [product information]. http://www.rxlist.com/cgi/generic3/tracleer.htm. Accessed: June 17 2012.

Giersbergen V.P.L., Halabi A., Dingemanse J. Pharmacokinetic interaction between bosentan and the oral contraceptives norethisterone and ethinyl estradiol // Int. J. Clin. Pharmacol. Ther. — 2006. — 44(3). — Р. 113-118.

Dingemanse J., Giersbergen V.P.L. Clinical pharmaco­logy of bosentan, a dual endothelin receptor antagonist // Clin. Pharmacokinet. — 2004. — 43(15). — Р. 1089-1115.

Giersbergen V.P.L., Popescu G., Bodin F., Dingemanse J. Influence of mild liver impairment on the pharmacokinetics and metabolism of bosentan, a dual endothelin receptor antagonist // J. Clin. Pharmacol. — 2003. — 43(1). — Р. 15-22.

Channick R.N., Simonneau G., Sitbon O. et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study // Lancet. — 2001. — 358. — Р. 1119-23.

Galie N., Hinderliter A.L., Torbicki A. et al. Effects of the oral endothelin-receptor antagonist Bosentan on echocardiographic and Doppler measures in patients with pulmonary arterial hypertension // J. Am. Coll. Cardiol. — 2003. — 41. — Р. 1380-6.

Rubin L.J., Badesch D.B., Barst R.J. et al. Bosentan therapy for pulmonary arterial hypertension // N. Engl. J. Med. — 2002. — 346. — Р. 896-903.

McLaughlin V.V., Sitbon O., Badesch D.B. et al. Survival with firstline bosentan in patients with primary pulmonary hypertension // Eur. Respir. J. — 2005. — 25. — Р. 244-9.

Keogh A.M., McNeil K.D., Wlodarczyk J. et al. Quality of life in pulmonary arterial hypertension: improved and maintained with bosentan // J. Heart Lung. Transplantation. — 2007. — 26. — Р. 181-7.

Barst R.J., Rubin L.J., Long W.A. et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group // N. Engl. J. Med. — 1996. — 334. — Р. 296-302.

D’Alonzo G.E., Barst R.J., Ayres S.M. et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry // Ann. Intern. Med. — 1991. — 115. — Р. 343-9.

Hoeper M.M. Pulmonary hypertension in collagen vascular disease // Eur. Respir. J. — 2002. — 19. — Р. 571-6.

Black C. Pulmonary arterial hypertension: are we doing enough to identify systemic sclerosis patients at high risk of this rare condition? // Rheumatology (Oxford). — 2005. — 44. — Р. 141-2.

Williams M.H., Das C., Handler C.E. et al. Systemic sclerosis associated pulmonary hypertension: improved survival in the current era // Heart. — 2006. — 92. — Р. 926-32.

Girgis R.E., Mathai S.C., Krishnan J.A. et al. Long-Term outcome of Bosentan treatment in idiopathic pulmonary arterial hypertension and pulmonary arterial hypertension associated with the scleroderma spectrum of diseases // J. Heart Lung Transplantation. — 2005. — 24. — Р. 1626-31.

Sitbon O., Gressin V., Speich R. et al. Bosentan in pulmonary arterial hypertension associated with HIV infection // Am. J. Respir. Crit. Care Med. — 2004. — 170. — Р. 1212-17.

Galie N., Beghetti M., Gatzoulis M.A., et al. Bosentan therapy in patients with Eisenmenger syndrome // Circulation. — 2006. — 114. — 48–54.

Kotlyar E., Sy R., Keogh A.M. Bosentan for the treatment of pulmonary arterial hypertension associated with congenital cardiac disease // Cardiol. Young. — 2006. — 16. — Р. 268-74.

Crepazet R., Romeo C., Montanaro D., De Santis S. Long-term results of treatment with bosentan in adult Eisenmenger’s syndrome patients with Down’s syndrome related to congenital heart disease // BMC Cardiovascular Disorders. — 2013. — 13. — Р. 74.

Hong-Yu Kuang, Yu-Hao Wu, Qi-Jian Yi, Jie Tian, Chun Wu, We Nian Shou, Tie-Wei Lu. The efficiency of endothelin receptor antagonist bosentan for pulmonary arterial hypertension associated with congenital heart disease A systematic review and meta-analysis // Medicine. — 2018. — 97. — 10(e0075).

Hughes R., George P., Parameshwar J. et al. Bosentan in inoperable chronic thromboembolic pulmonary hypertension // Thorax. — 2005. — 60. — Р. 707.

Hughes R.J., Jais X., Bonderman D. et al. Bosentan in inoperable chronic thromboembolic pulmonary hypertension: efficacy at 1 year // Eur. Respir. J. — 2006. — 28. — Р. 138-43.

Hoeper M.M., Kramm T., Wilkens H. et al. Bosentan Therapy for Inoperable Chronic Thromboembolic Pulmonary Hypertension // Chest. — 2005. — 128. — Р. 2363-7.

Bonderman D., Nowotny R., Skoro-Sajer N. et al. Bosentan Therapy for Inoperable Chronic Thromboembolic Pulmonary Hypertension // Chest. — 2005. — 128. — Р. 2599-603.

Musk M., Chambers D., Lawrence S. et al. Bosentan improves WHO functional class, exercise capacity and RV size in inoperable chronic thromboembolic pulmonary hypertension (CTEPH) // J. Heart Lung Transplantation. — 2006. — 25. — Р. 77.

Jais X., Ghofrani A., Hoeper M.M. et al. Bosentan for inoperable chronic thromboembolic pulmonary hypertension (CTEPH): a randomized, placebo-controlled trial // Am. J. Resp. Crit. Care Med. — 2007. — 173. — A896.

Chen X., Zhai Z., Huang Ke, Wanmu Xie Jun, Wan Chen Wang. Bosentan therapy for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: A systemic review and meta‐analysis // Clinical Respiratory Journal. — 2018. https://doi.org/10.1111/crj.12774

Barst R.J., Ivy D., Dingemanse J. et al. Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension // Clin. Pharmacol. Ther. — 2003. — 73. — Р. 372-82.

Rosenzweig E.B., Ivy D.D., Wilditz A. et al. Effects of long-term bosentan in children with pulmonary arterial hypertension // J. Am. Coll. Cardiol. — 2005. — 46. — Р. 697-704.

Berger R., Gehin M., Beghetti M., Dunbar Ivy, Andjela Kusic-Pajic A., Peter Cornelisse P., Grill S., Bonnet D. and the FUTURE-3 investigators. A bosentan pharmacokinetic study to investigate dosing regimens in paediatric patients with pulmonary arterial hypertension: FUTURE-3 // British Journal of Clinical Pharmacology. — 2017. — 83. — Р. 1734-1744.

Tabar M.L., Deshpande G., Xiao J. The use of bosentan in persistent pulmonary hypertension // Journal of Paediatrics and Child Health. — 2018. — 54(Suppl. 1). — Р. 3-128.

Gabbay E., Fraser J., McNeil K. Review of bosentan in the management of pulmonary arterial hypertension // Vascular Health and Risk Managemen. — 2007. — 3(6). — Р. 887-890.

Galiè N., Palazzini M., Manes A. Pulmonary arterial hypertension: from the kingdom of the near-dead to multiple clinical trial meta-analyses // Eur. Heart J. — 2010. — 31. — Р. 2080-2086.

Humbert M., Barst R.J., Robbins I.M. et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2 // Eur. Respir. J. — 2004. — 24. — Р. 353-359.

Kemp K., Savale L., O’Callaghan D.S. et al. Usefulness of first-line combination therapy with epoprostenol and bosentan in pulmonary arterial hypertension: an observational study // J. Heart Lung Transplant. — 2012. — 31. — Р. 150-158.

Sitbon O., Jaïs X., Savale L. et al. Upfront triple combination therapy in pulmonary arterial hypertension: a pilot study // Eur. Respir. J. — 2014. — 43. — Р. 1691-1697.

Galiè N., Barbera J.A., Frost A. et al. Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension // New Engl. J. Med. — 2015. — 379. — Р. 834-844.

Hoeper M.M., Faulenbach C., Golpon H. et al. Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension // Eur. Respir. J. — 2004. — 24. — Р. 1007-10.

Lunze K., Gilbert N., Mebus S. et al. First experience with an oral combination therapy using bosentan and sildenafil for pulmonary arterial hypertension // Eur. J. Clin. Invest. — 2006. — 36. — 3. — Р. 32-8.

Hoeper M.M., Kiely D.G., Carlsen J. et al. Safety profile of pulmonary arterial hypertension patients treated with bosentan and sildenafil: results from the European surveillance program // Am. J. Resp. Crit. Care Med. — 2005. — 169. — Р. 135.

McLaughlin V.V., Oudiz R.J., Frost A. et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension // Am. J. Respir. Crit. Care Med. — 2006. — 174. — Р. 1257-63.




Copyright (c) 2019 HYPERTENSION

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2018

 

   Seo анализ сайта